Citadel Advisors
TCRT icon

Citadel Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Citadel Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.1K Buy
+10,519
New +$31.5K ﹤0.01% 12570
2024
Q3 		– Sell
-1,691
Closed -$11.8K – 15233
2024
Q2 		$11.8K Buy
+1,691
New +$20.2K ﹤0.01% 13013
2023
Q3 		– Sell
-241
Closed -$10.4K – 15096
2023
Q2 		$18.4K Buy
241
+7
+3% +$566 ﹤0.01% 12798
2023
Q1 		$22.1K Sell
234
-4,790
-95% -$456K ﹤0.01% 12998
2022
Q4 		$489K Buy
5,024
+4,551
+962% +$660K ﹤0.01% 8289
2022
Q3 		$122K Buy
473
+358
+311% +$104K ﹤0.01% 10925
2022
Q2 		$22K Sell
115
-1,495
-93% -$143K ﹤0.01% 12369
2022
Q1 		$158K Sell
1,610
-39
-2% -$5.01K ﹤0.01% 11797
2021
Q4 		$270K Buy
1,649
+1,216
+281% +$267K ﹤0.01% 11147
2021
Q3 		$118K Sell
433
-1,205
-74% -$369K ﹤0.01% 12666
2021
Q2 		$649K Buy
+1,638
New +$765K ﹤0.01% 9422
2021
Q1 		– Sell
-1,312
Closed -$817K – 13704
2020
Q4 		$496K Sell
1,312
-1,405
-52% -$559K ﹤0.01% 8164
2020
Q3 		$1.03M Buy
2,717
+2,012
+285% +$889K ﹤0.01% 5987
2020
Q2 		$347K Sell
705
-408
-37% -$182K ﹤0.01% 7681
2020
Q1 		$409K Sell
1,113
-1,029
-48% -$532K ﹤0.01% 6791
2019
Q4 		$1.52M Buy
2,142
+1,761
+462% +$1.21M ﹤0.01% 4854
2019
Q3 		$244K Sell
381
-612
-62% -$485K ﹤0.01% 7874
2019
Q2 		$868K Buy
+993
New +$683K ﹤0.01% 5928
2019
Q1 		– Sell
-795
Closed -$332K – 9851
2018
Q4 		$223K Sell
795
-1,621
-67% -$641K ﹤0.01% 7708
2018
Q3 		$1.16M Buy
2,416
+227
+10% +$97.3K ﹤0.01% 5287
2018
Q2 		$992K Buy
2,189
+381
+21% +$242K ﹤0.01% 5229
2018
Q1 		$1.06M Buy
1,808
+111
+7% +$69.2K ﹤0.01% 4719
2017
Q4 		$1.05M Buy
1,697
+520
+44% +$374K ﹤0.01% 4583
2017
Q3 		$1.08M Sell
1,177
-95
-7% -$84.4K ﹤0.01% 4200
2017
Q2 		$1.19M Buy
1,272
+567
+80% +$556K ﹤0.01% 3844
2017
Q1 		$670K Buy
705
+64
+10% +$59.6K ﹤0.01% 4568
2016
Q4 		$515K Buy
641
+251
+64% +$226K ﹤0.01% 4853
2016
Q3 		$329K Sell
390
-4,394
-92% -$3.53M ﹤0.01% 5523
2016
Q2 		$3.94M Buy
+4,784
New +$5.21M ﹤0.01% 2033
2016
Q1 		– Sell
-737
Closed -$754K – 7921
2015
Q4 		$919K Sell
737
-1,946
-73% -$3.22M ﹤0.01% 3685
2015
Q3 		$3.63M Buy
2,683
+2,037
+315% +$3.36M ﹤0.01% 2261
2015
Q2 		$1.16M Buy
646
+370
+134% +$574K ﹤0.01% 3764
2015
Q1 		$447K Sell
276
-93
-25% -$138K ﹤0.01% 5067
2014
Q4 		$281K Sell
369
-242
-40% -$128K ﹤0.01% 5535
2014
Q3 		$242K Buy
611
+201
+49% +$96.9K ﹤0.01% 5518
2014
Q2 		$248K Buy
410
+222
+118% +$124K ﹤0.01% 5309
2014
Q1 		$129K Sell
188
-94
-33% -$63K ﹤0.01% 5939
2013
Q4 		$183K Buy
282
+230
+442% +$137K ﹤0.01% 5118
2013
Q3 		$31K Sell
52
-513
-91% -$231K ﹤0.01% 6024
2013
Q2 		$178K Buy
+565
New +$157K ﹤0.01% 4760

Other funds holding TCRT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's TCRT Position: Q1 2026 in Review

Citadel Advisors opened a new position in Alaunos Therapeutics (TCRT) in Q1 2026: 10,519 shares worth $30.1K. The stake represents ﹤0.01% of the portfolio and ranks #12570 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TCRT as recently as Q2 2024.

Citadel Advisors first reported a position in TCRT in Q2 2013 and has held it in 40 quarters since. The position peaked at $3.94M in Q2 2016. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.

  • Citadel Advisors held 10,519 shares of Alaunos Therapeutics worth $30.1K as of Q1 2026.
  • Alaunos Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Alaunos Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12570 holding.
  • Citadel Advisors first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • Citadel Advisors's Alaunos Therapeutics position peaked at $3.94M in Q2 2016.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.